anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
To achieve maximum contraceptive effectiveness, MICROGESTIN 1/20 and MICROGESTIN 1.5/30 should be taken exactly as directed and at intervals not exceeding 24 hours.

MICROGESTIN 1/20 and MICROGESTIN 1.5/30 provide a convenient tablet schedule of “3 weeks on-1 week off.” Two dosage regimens are described, one of which may be more convenient or suitable than the other for an individual patient. For the initial cycle of therapy, the patient begins her tablets according to the Day-1 or Sunday-Start regimen. With either regimen, the patient takes one tablet daily for 21 consecutive days followed by one week of no tablets.

A. Sunday-Start Regimen:

The patient begins taking the first white or green tablet from the top row of the dispenser (labeled Sunday) on the first Sunday after menstrual flow begins. When menstrual flow begins on Sunday, the first white or green tablet is taken on the same day. The patient takes one white or green tablet daily for 21 days. The last white or green tablet will be taken on a Saturday, followed by no tablets for a week (7 days). For all subsequent cycles, the patient begins a new 21-tablet regimen on the eighth day, Sunday, after taking her last tablet. Following this regimen of 21 days on-7 days off, the patient will start all subsequent cycles on a Sunday.

B. Day-1 Start Regimen:

The first day of menstrual flow is Day 1. The patient starts taking one white or green tablet daily, beginning with the first white or green tablet in the top row. After the last white or green tablet (Saturday) has been taken, if any white or green tablets remain in the top row, the patient takes the remaining white or green tablets starting with the Sunday white or green tablets in the top row until all of the tablets have been taken. She will then take no tablets for a week (7 days). For all subsequent cycles, the patient begins a new 21- tablet regimen on the eighth day after taking her last white or green tablet, again starting with the first tablet in the top row. Following this regimen of 21 days on–7 days off, the patient will start all subsequent cycles on the same day of the week as the first course. Likewise, the interval of no tablets will always start on the same day of the week.

Tablets should be taken regularly with a meal or at bedtime. It should be stressed that efficacy of medication depends on strict adherence to the dosage schedule.
Mediterranean diet was applied to this group according to the needs of the individuals. The explanation was made through the Mediterranean diet training document and sample menu prepared by the researcher. The individuals were asked to apply this diet for 12 weeks. The individuals' compliance with the diet was evaluated with food consumption records in 4-week periods. Blood samples were taken from the individuals at the beginning of the treatment as biological material and at the end, blood samples and follicle fluid samples were collected according to the adjuvant treatment. Fatty acid analyses were performed with gas chromatography.
Cohort 3 includes approximately 1350 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant. Financial barriers are removed for Period 3 participants and they can initiate which ever contraceptive method they want at no cost to them for three years. During enrollment period 3, a community-wide, media driven intervention will be implemented and population level changes in HER-C initiation will be examined.
Antenatal hypoxia-ischaemia (HI) in preterm fetal sheep can trigger delayed evolution of severe, cystic white matter injury (WMI), in a similar timecourse to WMI in preterm infants. We therefore examined how severe hypoxia-ischaemia affects recovery of electroencephalographic (EEG) activity. Chronically instrumented preterm fetal sheep (0.7 gestation) received 25 min of complete umbilical cord occlusion (UCO, n = 9) or sham occlusion (controls, n = 9), and recovered for 21 days. HI was associated with a shift to lower frequency EEG activity for the first 5 days with persisting loss of EEG power in the delta and theta bands, and initial loss of power in the alpha and beta bands in the first 14 days of recovery. In the final 3 days of recovery, there was a marked rhythmic shift towards higher frequency EEG activity after UCO. The UCO group spent less time in high-voltage sleep, and in the early evening (7:02 pm ± 47 min) abruptly stopped cycling between sleep states, with a shift to a high frequency state for 2 h 48 min ± 40 min, with tonic electromyographic activity. These findings demonstrate persisting EEG and sleep state dysmaturation after severe hypoxia-ischaemia. Loss of fetal or neonatal sleep state cycling in the early evening may be a useful biomarker for evolving cystic WMI.
The invention concerns a composition for a softening lotion which is liquid at a temperature of at least 5° C. and which is meant to be used in treating an absorbent paper product. In the invention, this composition comprises: (a) from 1 to 10% by wt. of a component essentially containing a quaternary ammonium compound; (b) from 5 to 99% by wt. of an aqueous emollient component which contains, as active substances: (i) one or more saturated linear fatty alcohols having at least 16 carbon atoms, (ii) one or more waxy esters having a total of at least 24 carbon atoms and, where called for, (iii) one or more nonionic and/or amphoteric emulsifiers; and (c) a balance to 100% by wt. of the required amount of a solvent of the type polyol, mineral oil or their mixtures. The invention relates to the manufacture of absorbent paper products.
Sapogenin is obtained from plant material containing its glycosides or other derivatives, e.g. from sisal and other plants of the genus Agave, by separating the plant juice from the plant material, allowing the juice to ferment, and collecting the resultant sludge from which the sapogenin is recovered; subsequently, heating the sludge with a small proportion of mineral acid to agglomerate the finer solid particles therein, collecting the sludge solids, heating the sludge solids with mineral acid for a time and at a temperature sufficient to effect substantial hydrolysis thereof, removing the alcohol by steam distillation if alcoholic acid is employed for the hydrolysis, and collecting the nonaqueous phase from the resultant suspension, and extracting the collected material by means of an organic solvent to produce hecogenin.  The water-insoluble solids resulting from the acid hydrolysis may be treated with an adsorbent material, e.g. activated charcoal, prior to decantation, filtration &c.  As an alternative process the hecogenin can be obtained by direct extraction of the dried plant juice sludge with an organic fat solvent, e.g. isopropyl ether or carbon tetrachloride. Specifications 702,072 and 722,186 are referred to.
Pervasive Developmental Disorders is a category of disorders that includes autism and related conditions. While these disorders are rare, they represent a significant public health problem because they are extremely debilitating and lack efficacious therapies. Neuroleptic use in PDD is high and the population appears to be at increased risk of serious sequelae including tardive dyskinesia. Newer atypical neuroleptics including risperidone are now used in 87% of cases but dosing, safety and efficacy is undetermined in the vulnerable population.

This study consists of a total of 3 visits, the initial screening visit where consent, medical history, demographics and vitals will be recorded. Two additional visits with blood sampling will occur. The second visit will be no greater than 30 days from the screening visit and the 3rd visit will be one month from Visit 2.
Ticagrelor is an oral antiplatelet agent which was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011. It is available as round, yellow tablets (90 mg). The standard dose is 90 mg twice a day during the maintenance phase and 180 mg once for the loading dose. It is approved for duration of 12 month in ACS patients and will be used for duration of one month in the ALPHEUS Study.
255,456. Gl³cksmann, E. July 14, 1925, [Convention date]. Emulsions, making; medicines for internal use. -Aqueous emulsions of paraffin, for medicinal use, are prepared by the combined use of two emulsifying agents, a vegetable gum and "algae," the product being of pudding-like consistency. Flavouring matter may be added to the water of which the emulsion is made. According to one example, 1 kilo of agar whilst being heated is dissolved in 50 kilos of water and to it are added 1 kilo of swelled tragacanth and a solution of 6-8 kilos of sugar in 5 kilos of water. The mixture is stirred with 35 kilos of paraffin-oil. In another example, 1 kilo of agar, whilst being heated, is dissolved in 25 kilos of water and to it are added 0.5-1 kilo of gum arabic swelled in water, 6-8 kilos of sugar, and 1 kilo of swelled gelatine. The solution is stirred with 70 kilos of paraffin-oil..
The present invention relates to a preparation technology and a production method for an integrated new formulation of a dichroa leaf powder, wherein the raw materials of active ingredients comprise: 10 parts by weight of dichroa leaf (washed for removal of fishy taste), 10 parts by weight of mica (burned for two days and nights) and 10 parts by weight of dragon bone. The production process of the dichroa leaf powder comprises the following steps of: supersonic air-jet crushing, alcohol-water extraction, ultrasonic crushing extraction, water decocting concentration, supersonic spray drying, nanometer grinding, high pressure homogenization, nano particle preparation and the like. According to the invention, the advantages, such as multi-synergism, multi-target, embodied by a nano-carrier coupling technique, are focused to be taken of. After the integrated new formulation of dichroa leaf powder is subjected to scale production, the production cost can be greatly reduced, the quality of products is greatly improved and the targeting property and the sustained and controlled release performance of the medicament are enhanced. The internal and external administration of the integrated new formulation of dichroa leaf powder can be realized simultaneously, and can be respectively taken in four time slices according to midnight-noon ebb-flow and qi and blood flowing rule of a human body. The integrated new formulation of dichroa leaf powder can be further prepared into films and transdermal agents which are respectively stuck to different parts of a human body according to the midnight-noon ebb-flow and qi and blood flowing rule of the human body and can be directly absorbed through skin.
Those assigned to the waitlist will simply wait 8 weeks. A second online assessment will be completed 8 weeks after baseline in both conditions (for a between condition comparison). After the second assessment, waitlist participants will gain access to ACT on Health.
An individualized Otago Exercise Program will be delivered by community health representatives (CHR) in participants homes. There will be 10 home visits over a 12 month period.
In some embodiments, a patient dataset including digital medical images and other patient data may be obtained. The other patient data may include specific patient health data associated with a patient and historical patient data derived from a population related to the patient. The historical patient data may indicate medical inventions provided to patients of the related population, health effects of the medical interventions, and costs of the medical interventions. In some embodiments, a neural network specific to the patient may be configured for a user application using at least part of the patient dataset. As an example, the user application may include neural network. Based on the specific patient health data, health effects and intervention costs related to individual interventions for the patient may be predict via the neural network of the user application. The net health benefits for the individual interventions may be provided via the user interface based on the predicted health effects and intervention costs.
LETS ACT is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, \& Hopko, 2001). LETS ACT is based on the belief that the best way to improve mood, remain sober, and to make long-term life changes is by changing and increasing one's activity level. It has been modified to accommodate the needs of a substance using population currently receiving inpatient substance use treatment. Treatment is provided over a 4-week period and is provided in small group format, with each group consisting of 3-5 patients.
The current study aims to evaluate the Jaspr app relative to usual care among youth (ages 13-21 years) who indicate suicidal ideation in pediatric outpatient medical settings. The Jaspr app includes supported safety planning between the young person and the healthcare provider, as well as skills and support videos for youth and caregivers intended to increase coping and decrease distress with an opportunity to access these resources through an at home app. Adolescents, parents, and clinicians will participate in the project to assess the effectiveness of Jaspr augmenting usual care, compared to usual care alone. The study will use a pre-post design in which each clinic begins with a control period and then transitions to the addition of Jaspr following healthcare provider training on use of the app. Participants and their parents will receive study assessments at baseline, 1-month, and 2-month follow up timepoints, and healthcare providers complete a survey at baseline, the end of the control period, and the end of the intervention period. Study assessments with youth will ask about coping, suicidal ideation and severity, anxiety and depression, service utilization, functional impairment, access to lethal means, therapeutic alliance, and satisfaction with care and the app. Study assessments for parents will ask about their self-efficacy in managing their youth's suicidality, service utilization for the youth, and satisfaction with care. Healthcare providers will complete surveys assessing their self-efficacy in managing youth suicidality. Youth, their legal guardian, and healthcare providers each assent/consent to participate in the research procedures.
Visual impairment is a broad term that describes a wide continuum of loss in visual function. There are many aspects of visual function e.g., visual acuity(ability to resolve detail),accommodation (ability to focus), field of vision (area which can be seen), colour vision and adapt ability to light. A child with cerebral blindness may have intact perception of movement. Prevalence data can be obtained from a variety of different sources, each of which has limitations. Reducing visual impairment and blindness in children in resource-poor countries is one of the key components of the major global prevention of blindness initiative, VISION 2020 the Right to Sight. Visually impaired children especially with hereditary /congenital ocular anomalies benefit from refraction and low vision services which facilitate vision enhancement and inclusive education. Pediatricians have a key role in early detection and multidisciplinary management to minimise the impact of visual impairment (VI) in childhood.Visually impaired children especially with hereditary /congenital ocular anomalies benefit from refraction and low vision services which facilitate vision enhancement and inclusive Powerball® is such a market existing device that can be used for wrist rehabilitation and also as a sports aid for strengthening the wrist. The Powerball acts as an eccentric exercise tool, generating forces in different directions and thus causing stimulation of the forearm, hand, and wrist musculature. The tools used will be handheld dynamometer and pegboard test. Study will be conducted on Twenty eight patients in two Groups. .Group A will be Control Group that will be provided with conventional physiotherapy (isometric hand grip training exercises) and Group B will be Experimental Group that Conventional treatment with power ball training. Data will be analyzed using spss 22.0
The investigators will define the most appropriate safe dose of D50 to heal air leaks in patients that have undergone lung resection surgery (Phase I study). Air leaks from unhealed lung tissue are one of the most common complications after lung surgery including wedge resection, segmentectomy and lobectomy. Air leaks can lead to a delay in chest tube removal, prolonged pain, increased infections, prolonged hospital stay, and increased costs to the health care system. Different agents have been used to heal air leaks by creating a pleurodesis (adhesions to obliterate the pleural space between the visceral and parietal pleura). The success with these agents has been variable and come with the cost of complications that have restricted their use the post-operative period. There has been recent interest in the use of 50% hypertonic glucose (D50) to create pleurodesis with encouraging reports coming mostly from Asia. The investigators have performed a pilot study using 180 mL of D50 instilled through the chest tube for the management of post lobectomy air leak with very encouraging results. This preliminary study used strict inclusion criteria of only lobectomy patients and excluded all patients with known diabetes or any postoperative hyperglycemia. It is unknown if these patients would have benefitted from D50. Also, the optimal dose of D50 was chosen empirically and never clearly defined by previous work. It has been reported that high doses of D50 have been associated with acute lung injury. It is therefore critical that the optimal safe dose is clarified.
FIELD: medicine, steroid chemistry, contraceptives. SUBSTANCE: invention relates to compositions for local administration and forms for subcutaneous incorporation. These implants involve an effective dose of derivative of 3,20-dioxo-6-methyl,17-acetoxy-19-norpregna-4,6-diene substituted at 3 and/or 17 position at random and bound or mixed with biologically acceptable inert carrier. These compositions are effective contraceptive agents exhibiting the prolonged active effect, at least, for one year at minimal adverse effects. EFFECT: enhanced effectiveness of new compositions. 4 cl, 3 tbl, 5 dwg
This study aimed to investigate the differences in cerebellar volumes and intrinsic cerebellar networks between patients with transient global amnesia (TGA) and healthy controls. We retrospectively enrolled patients with TGA and age- and sex-matched healthy controls. We used three-dimensional T1-weighted imaging at the time of TGA diagnosis to obtain cerebellar volumes, and the intrinsic cerebellar network was calculated by applying graph theory based on cerebellar volumes. The nodes were defined as individual cerebellar volumes, and edges as partial correlations, controlling for the effects of age and sex. The cerebellar volumes and intrinsic cerebellar networks were compared between the two groups. We enrolled 44 patients with TGA and 47 healthy controls. The volume of the left cerebellar white matter in patients with TGA was significantly lower than that in healthy controls (1.0328 vs. 1.0753%, p = 0.0094). In addition, there were significant differences in intrinsic cerebellar networks between the two groups. The small-worldness index in patients with TGA was higher than that in the healthy controls (0.951 vs. 0.880, p = 0.038). In the correlation analysis, the volumes of the right cerebellar cortex and lobules VIIIB were significantly correlated with age in patients with TGA (r = -0.323, p = 0.033; r = -0.313, p = 0.038, respectively). Patients with TGA exhibit alterations in cerebellar volumes and intrinsic cerebellar networks compared with healthy controls. These findings may contribute to a better understanding of the pathophysiology of the TGA.
OBJECTIVES: I. Assess the efficacy of high dose cytarabine with mitoxantrone and amifostine as induction therapy for patients with previously untreated standard risk acute myelogenous leukemia (AML). II. Assess the effects of amifostine on the biology of AML cells in vivo in these patients. III. Determine whether there is a relationship between cytokine production before and during remission induction therapy and treatment outcome.

OUTLINE: Prior to treatment, patients undergo bone marrow aspirate and biopsy. On day -3, patients receive idoxuridine IV over 60 minutes followed immediately by a bone marrow aspirate and biopsy. Patients then receive amifostine IV over 5-7 minutes on the same day. Prior to chemotherapy on day 1, patient receive broxuridine IV over 60 minutes immediately followed by bone marrow aspirate and biopsy. Chemotherapy on day 1 consists of amifostine followed by cytarabine IV over 3 hours repeated every 12 hours and mitoxantrone IV over 1 hour immediately after the second infusion of cytarabine. This course is repeated on day 5 after another bone marrow biopsy and aspirate. Starting on day 6, patients receive amifostine 3 times a week until day 28 or beyond. Patients who respond to treatment continue on to receive three courses of consolidation therapy. Consolidation courses 1 and 3 consist of cytarabine continuous IV on days 1-7 and idarubicin IV over 30 minutes on days 1, 2, and 3. Consolidation course 2 consists of cytarabine IV over 75 minutes repeated every 12 hours for 4 days. Twenty-four hours after each course of consolidation therapy, patients receive isotretinoin orally every day and interferon alfa subcutaneously every other day. Isotretinoin and interferon alfa therapy are stopped 4 days prior to day 1 of the next course of consolidation therapy. Following recovery from course 3 of consolidation therapy, patients continue to receive isotretinoin/interferon alfa until relapse. Patients in complete remission after the 3 courses of consolidation therapy receive isotretinoin/interferon alfa for 3 years. Patients are followed every 3 months for the first year, then every 6 months for the next 2 years.

PROJECTED ACCRUAL: There will be 40-45 patients accrued into this study.
This study is a domestic, multi-center, prospective, observational study designed for locally advanced or metastatic pancreatic cancer patients who plan to receive palliative chemotherapy. When patients voluntarily express their consent to provide their information to this study by signing a written agreement, their baseline information including demographics, comorbidities, pancreatic cancer-related information, medical treatment history, etc. shall be used for screening. When patients are judged eligible for study participation, they shall receive an appropriate palliative chemotherapy. After first-line chemotherapy (baseline), information review shall be conducted at month 2, 6 and 12 for chemotherapy currently in use (whether or not chemotherapy ended/discontinued and relevant reasons; type, frequency and duration of administered drugs), RECIST, quality of life (month 2 and 6), activity performance assessment, laboratory tests, tumor marker test, adverse drug reactions, etc. However, if first-line chemotherapy moves to second-line chemotherapy due to causes such as progressive disease (PD), information review shall be restricted to the relevant drug name and survival until the end of the study (month 12).